Literature DB >> 29411299

A rare CALR variant mutation and a review of CALR in essential thrombocythemia.

Robert Diep1,2, Ara Metjian3,4.   

Abstract

Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm characterized by megakaryocyte hyperplasia, thrombocytosis, thrombotic and hemorrhagic complications, and potential transformation into myelofibrosis and acute myeloid leukemia. The vast majority of cases are driven by a somatic mutation in JAK2, CALR, or MPL. CALR, a gene that codes for the calcium-binding chaperone calreticulin, is the predominant mutation in patients with non-mutated JAK2 essential thrombocythemia, accounting for 20-25% of the overall somatic mutation frequency in ET. In this brief review of ET, we introduce a rare CALR mutation through a case presentation of a 58-year-old man with diffuse pulmonary emboli in the setting of thrombocytosis. We subsequently characterize the main types of CALR mutations and their value in diagnosis and prognosis of disease course, and lastly discuss the current clinical approach to ET.

Entities:  

Keywords:  CALR; Essential thrombocythemia; Myeloproliferative disorders; Thrombocytosis

Mesh:

Substances:

Year:  2018        PMID: 29411299     DOI: 10.1007/s11239-018-1619-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

Review 1.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

2.  Therapeutic cytapheresis: too many platelets, too many white blood cells.

Authors:  Deanna Duvall
Journal:  J Clin Apher       Date:  2010-12-13       Impact factor: 2.821

3.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

4.  JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Authors:  Lisa Pieri; Alessandro Pancrazzi; Annalisa Pacilli; Claudia Rabuzzi; Giada Rotunno; Tiziana Fanelli; Paola Guglielmelli; Rajmonda Fjerza; Chiara Paoli; Srdan Verstovsek; Alessandro M Vannucchi
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

5.  Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

Authors:  Guido Finazzi; Alessandra Carobbio; Paola Guglielmelli; Chiara Cavalloni; Silvia Salmoiraghi; Alessandro M Vannucchi; Mario Cazzola; Francesco Passamonti; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2014-10-16       Impact factor: 22.113

Review 6.  Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.

Authors:  Ayalew Tefferi; Tiziano Barbui
Journal:  Mayo Clin Proc       Date:  2015-09       Impact factor: 7.616

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  Platelet activation and inhibition in polycythemia vera and essential thrombocythemia.

Authors:  Carlo Patrono; Bianca Rocca; Valerio De Stefano
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

9.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Authors:  D Pietra; E Rumi; V V Ferretti; C A Di Buduo; C Milanesi; C Cavalloni; E Sant'Antonio; V Abbonante; F Moccia; I C Casetti; M Bellini; M C Renna; E Roncoroni; E Fugazza; C Astori; E Boveri; V Rosti; G Barosi; A Balduini; M Cazzola
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

10.  Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Authors:  T Barbui; A M Vannucchi; V Buxhofer-Ausch; V De Stefano; S Betti; A Rambaldi; E Rumi; M Ruggeri; F Rodeghiero; M L Randi; I Bertozzi; H Gisslinger; G Finazzi; A Carobbio; J Thiele; F Passamonti; C Falcone; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-27       Impact factor: 11.037

View more
  1 in total

1.  Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review.

Authors:  Rong Chen; Xiaodan Shi; Luojun Wang; Xuan Wang; Jingya Wei; Xiaogang Kang; Fang Du; Shan Gao; Fang Yang; Wen Jiang
Journal:  Ther Adv Neurol Disord       Date:  2022-04-26       Impact factor: 6.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.